Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Takeda at: AE.GBR-IRL@takeda.com.

Download and print resources that may help you and your patients in the management of appropriate SBS-IF adult and child patients with Revestive▼(teduglutide). Some materials are also available to order.

Measuring the benefits and mitigating the risks of Revestive

A guide to discuss who may be prescribed Revestive, potential benefits & risks from treatment & what a typical treatment plan may look like

Download PDF

Revestive Leave piece - Paediatric patients

This leave piece summarises key efficacy and safety data for Revestive's use in children

Download PDF

Revestive Leave piece - Adult patients

This leave piece summarises key efficacy and safety data for Revestive's use in adults

Download PDF

Revestive Practical Guide (paediatric patients)

A practical guide to support you with identifying, treating and monitoring paediatric patients

Download PDF

Revestive Practical Guide (adult patients)

A practical guide to support you with identifying, treating and monitoring adult patients

Download PDF

IBD Empower Module 8: Managing intestinal failure in adults

This educational module is part of a series of educational resources from the IBD Empower programme which supports healthcare professionals working in intestinal failure and inflammatory bowel disease (IBD) enabling them to support their patients more effectively.

To request access to this module, contact us on: ibd.empower@takeda.com

C-APROM/GB/REV/0346 Date of preparation April 2026